Abstract: In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured. The variables shown in Formula AA are as defined in the claims. The compounds of formula AA are NLRP3 activity modulators and, as such, can be used in the treatment of metabolic disorders (e.g. Type 2 diabetes, atherosclerosis, obesity or gout), a disease of the central nervous system (e.g. Alzheimer's disease, multiple sclerosis, Amyotrophic Lateral Sclerosis or Parkinson's disease), lung disease (e.g. asthma, COPD or pulmonary idiopathic fibrosis), liver disease (e.g. NASH syndrome, viral hepatitis or cirrhosis), pancreatic disease (e.g. acute pancreatitis or chronic pancreatitis), kidney disease (e.g. acute kidney injury or chronic kidney injury), intestinal disease (e.g. Crohn's disease or Ulcerative Colitis), skin disease (e.g. psoriasis), musculoskeletal disease (e.g. scleroderma), a vessel disorder (e.g. giant cell arteritis), a disorder of the bones (e.g.

Abstract: A board defect filtering method is provided. The method includes: receiving a defect list; obtaining a plurality of defect images of a plurality of defect records on the defect list; receiving a circuit layout image; analyzing a defect location of a first defect image of the plurality of defect images according to the circuit layout image; cropping the first defect image to obtain a first cropped defect image according to the defect location; inputting the first cropping defect image to a defect classifying model; and determining whether the first defect image is a qualified product image or not according to an output result of the defect classifying model.

Abstract: The present invention relates to a compound represented by formula I?: and pharmaceutically acceptable salts thereof. The compounds of formula I are inhibitors of diacylglyceride O-acyltransferase 2 (“DGAT2”) and may be useful in the treatment, prevention and suppression of diseases mediated by DGAT2. The compounds of the present invention may be useful in the treatment of hepatic steatosis, diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, cardiorenal diseases such as chronic kidney diseases and heart failure and related diseases and conditions.

Abstract: A mixed rope used for oceanographic buoy mooring system, comprises mixed core rope of metal and fiber and cover rope, wherein, the mixed core rope of metal and fiber comprises metal coil spring and fiber supporting core inside the metal coil spring; the cover rope is woven of several number of twisted strand; the mass content of the mixed core rope of metal and fiber is not greater than 20% of the mass of mixed rope, the mass content of the cover rope is not less than 80% of the mass of the mixed rope. Mixed rope used for oceanographic mooring system disclosed in present embodiments has small linear density and high fracture strength, may be used as data communication channel from under-water sensor to the over-water receiver, being soft, light and easy to deploy, the mixed rope can be used as the upper part of the oceanographic buoy mooring system with prospective application.

Abstract: In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured. The variables shown in Formula AA are as defined in the claims. The compounds of formula AA are NLRP3 activity modulators and, as such, can be used in the treatment of metabolic disorders (e.g. Type 2 diabetes, atherosclerosis, obesity or gout), a disease of the central nervous system (e.g. Alzheimer's disease, multiple sclerosis, Amyotrophic Lateral Sclerosis or Parkinson's disease), lung disease (e.g. asthma, COPD or pulmonary idiopathic fibrosis), liver disease (e.g. NASH syndrome, viral hepatitis or cirrhosis), pancreatic disease (e.g. acute pancreatitis or chronic pancreatitis), kidney disease (e.g. acute kidney injury or chronic kidney injury), intestinal disease (e.g. Crohn's disease or Ulcerative Colitis), skin disease (e.g. psoriasis), musculoskeletal disease (e.g. scleroderma), a vessel disorder (e.g. giant cell arteritis), a disorder of the bones (e.g.

Abstract: A package structure is provided. The package structure includes a substrate. The package structure also includes a hybrid pad disposed on the substrate. The hybrid pad includes a metal layer and a buffer layer connected to the metal layer. The Young's modulus of the buffer layer is less than the Young's modulus of the metal layer. The package structure further includes an electrically connecting structure disposed on the hybrid pad. The package structure includes a chip layer electrically connected to the electrically connecting structure. The package structure also includes a bonding pad disposed between the electrically connecting structure and the chip layer.

Abstract: The present disclosure relates to a radio-frequency identification system for a container, such as a cryogenic container, comprising: a large number of radio-frequency identification tags for cryogenic straws, preferably at least 100 radio-frequency identification tags, each radio-frequency identification tag attachable to or embeddable in a cryogenic straw; an interrogation unit adapted to be placed or integrated inside the cryogenic container; wherein the interrogation unit and radio-frequency identification tags are configured to operate with a frequency of at least 30 MHz.

Abstract: An electronic device including a holder, a first buffer element, a second buffer element and a loudspeaker is provided. The holder includes a first section and a second section perpendicular to the first section. The first section and the second section are respectively provided with a first opening and a second opening. The first buffer element is disposed in the first opening of the first section. The second buffer element is disposed in the second opening of the second section. The loudspeaker is supported on the housing by the holder. The first buffer element is connected to the loudspeaker, and the second buffer element is connected to the housing.

Abstract: In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured. The variables shown in Formula AA are as defined in the claims. The compounds of formula AA are NLRP3 activity modulators and, as such, can be used in the treatment of metabolic disorders (e.g. Type 2 diabetes, atherosclerosis, obesity or gout), a disease of the central nervous system (e.g. Alzheimer's disease, multiple sclerosis, Amyotrophic Lateral Sclerosis or Parkinson's disease), lung disease (e.g. asthma, COPD or pulmonary idiopathic fibrosis), liver disease (e.g. NASH syndrome, viral hepatitis or cirrhosis), pancreatic disease (e.g. acute pancreatitis or chronic pancreatitis), kidney disease (e.g. acute kidney injury or chronic kidney injury), intestinal disease (e.g. Crohn's disease or Ulcerative Colitis), skin disease (e.g. psoriasis), musculoskeletal disease (e.g. scleroderma), a vessel disorder (e.g. giant cell arteritis), a disorder of the bones (e.g.

Abstract: An assembly includes a front console having an outer surface and a pair of outboard ends spaced along an axis and defining a center therebetween. The assembly includes an airbag supported by the front console at one of the outboard ends and inflatable from an uninflated position elongated transverse to the axis to an inflated position extending along the outer surface toward the center.

Abstract: Disclosed are embodiments of rope designs and making and manufacturing of such ropes. In some embodiments, a rope comprises a set of first rope cores, each first rope core of the set of first rope cores comprising a first material; a set of second rope cores, each second rope core of the set of second rope cores comprising a second material, the second material being different from the first material; and a rope sheath configured to encompass the set of first rope cores and the second rope core. In some cases, the rope sheath is braided from a plurality of rope sheath strands.

Abstract: The present invention relates to a compound represented by formula I: and pharmaceutically acceptable salts thereof. The compounds of formula I are inhibitors of diacylglyceride O-acyltransferase 2 (“DGAT2”) and may be useful in the treatment, prevention and suppression of diseases mediated by DGAT2. The compounds of the present invention may be useful in the treatment of hepatic steatosis, diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, nonalcoholic steatohepatitis (NASH), cardiorenal diseases such as chronic kidney diseases and heart failure and related diseases and conditions.

Abstract: A red light emitting diode including an epitaxial stacked layer, a first and a second electrodes and a first and a second electrode pads is provided. The epitaxial stacked layer includes a first-type and a second-type semiconductor layers and a light emitting layer. A main light emitting wavelength of the light emitting layer falls in a red light range. The epitaxial stacked layer has a first side adjacent to the first semiconductor layer and a second side adjacent to the second semiconductor layer. The first and the second electrodes are respectively electrically connected to the first-type and the second-type semiconductor layers, and respectively located to the first and the second sides. The first and a second electrode pads are respectively disposed on the first and the second electrodes and respectively electrically connected to the first and the second electrodes. The first and the second electrode pads are located at the first side of the epitaxial stacked layer.

Abstract: An assembly includes a front console having an outer surface and a pair of outboard ends spaced along an axis and defining a center therebetween. The assembly includes an airbag supported by the front console at one of the outboard ends and inflatable from an uninflated position elongated transverse to the axis to an inflated position extending along the outer surface toward the center.

Abstract: A light emitting diode and manufacturing method thereof are provided. The light emitting diode includes a first-type semiconductor layer, a light emitting layer, a second-type semiconductor layer, a first metal layer, a first current conducting layer, a first bonding layer and a second current conducting layer. The light emitting layer is located between the first-type semiconductor layer and the second-type semiconductor layer. The first metal layer is located on and electrically connected to the first-type semiconductor layer. The first metal layer is located between the first current conducting layer and the first-type semiconductor layer. The first current conducting layer is located between the first bonding layer and the first metal layer. The first current conducting layer is connected to the first-type semiconductor layer by the first current conducting layer and the first metal layer. The first bonding layer has through holes overlapped with the first metal layer.

Abstract: An electronic stylus includes a hollow cylindrical casing having an opening defined in an axial end portion thereof, a core body mounted in the casing and having an axial end portion projecting out of the opening, and a core body protector covering and accommodating therein the axial end portion of the core body, and protecting the core body. The casing has, adjacent to the opening, an abutment surface lying in a direction transverse to an axial direction of the casing and an inner wall surface extending in the axial direction of the casing. The core body protector has a first surface facing the abutment surface of the casing and a second surface facing the inner wall surface of the casing.

Abstract: The invention provides an LED including a first-type semiconductor layer, an emitting layer, a second-type semiconductor layer, a first electrode, a second electrode, a Bragg reflector structure, a conductive layer and insulation patterns. The first electrode and the second electrode are located on the same side of the Bragg reflector structure. The conductive layer is disposed between the Bragg reflector structure and the second-type semiconductor layer. The insulation patterns are disposed between the conductive layer and the second-type semiconductor layer. Each insulating layer has a first surface facing toward the second-type semiconductor layer, a second surface facing away from the second-type semiconductor layer, and an inclined surface. The inclined surface connects the first surface and the second surface and is inclined with respect to the first surface and the second surface.

Abstract: A light emitting diode (LED) including an epitaxial stacked layer, first and second reflective layers which are disposed at two sides of the epitaxial stacked layer, a current conducting layer and first and second electrodes and a manufacturing thereof are provided. The epitaxial stacked layer includes a first-type and a second-type semiconductor layers and an active layer. A main light emitting surface with a light transmittance >0% and ?10% is formed on one of the two reflective layers. The current conducting layer contacts the second-type semiconductor layer. The first electrode is electrically connected to the first-type semiconductor layer. The second electrode is electrically connected to the second-type semiconductor layer via the current conducting layer. A contact scope of the current conducting layer and the second-type semiconductor layer is served as a light-emitting scope overlapping the two layers, but not overlapping the two electrodes.

Abstract: A film for inhibiting corrosion including a polymeric resin and a vapor corrosion inhibitor film additive is described. The vapor corrosion inhibitor film additive includes compounds useful to protect metal surfaces from corrosion, such as ammonium or alkylammonium carboxylates and/or a triazole derivative. The film may include multiple layers.

Abstract: A projector includes a casing, a lens, a bracket, a support member, a first spacer and a first fixing member. The lens is connected to the casing. The bracket is connected to the casing and has a through hole formed thereon. The support member is inserted into the through hole and abuts against the lens. The first spacer is disposed on the support member and has a first curved surface and the first curved surface faces the through hole. The first fixing member is disposed on the support member and pushes the first spacer towards the bracket, such that the first curved surface contacts a periphery of the through hole.